Full Press Release Details
Therapeutics Announces Proposed Public Offering of Common Shares
and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to
transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering
is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the size
or terms of the offering. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides
that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such
is acting as sole placement agent for the offering.
Company intends to use the net proceeds from the offering primarily for working capital requirements, general corporate purposes, and
the advancement of business objectives.
securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus,
filed with the U.S. Securities and Exchange Commission (the "SEC") on January 22, 2024 and declared effective on January
31, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus
describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity,
17 State Street, 41st Floor, New York, New York 10004. Before investing in this offering, interested parties should read in
their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed
with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide
more information about the Company and such offering.
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of such state or jurisdiction.
BriaCell Therapeutics Corp.
is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties.
All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking
statements contained in this press release may be identified by the use of words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project," "target,"
"aim," "should," "will," "would," or the negative of these words or other similar expressions,
although not all forward-looking statements contain these words. Forward-looking statements, including those about the use of proceeds
of the proposed offering, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions
that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not
prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risk Factors" in
the Company's most recent Annual Report on Form 10-K, and under "Risks and Uncertainties" in the Company's other
filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available
under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in
this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required
under applicable law.
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
William V. Williams, MD